Program
mazdutide
Also written as “IBI362”, “LY3305677” and “Mazdutide”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Overweight · Fatty Liver · Alcoholism, led by 2 companies.
Drug pageMazdutide: every studyAll 44 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 208 open or running | phase 3since Oct 19, 2022 | Jun 5, 2020 | Dec 31, 2026phase 3 · NCT06884293 |
| Eli Lillyits history only | 71 open or running | phase 2since Nov 6, 2023 | Nov 21, 2016 | Sep 2027phase 2 · NCT06143956 |
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseInnovent licensed it from Lilly, for China.Announced Aug 21, 2019 · Source: Innovent (release), Aug 21, 2019
History and studies of Innovent Biologics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 3 earlier studies, Jun 5, 2020 to Feb 21, 2021.
- Aug 21, 2019Innovent licensed it from LillyLicenseChina · announced · Innovent (release)
- May 25, 2021Phase 2 study in Overweight/ ObesityNCT04904913 · 328 enrolled · China
- Jul 15, 2021Phase 2 study in Diabetes Mellitus, Type 2NCT04965506 · 252 enrolled · China
- Jan 25, 2022Named mazdutideINNProposed as its International Nonproprietary Name in WHO's List 126 · before, IBI362, LY3305677
- Oct 19, 20222 phase 3 studiesNCT05606913, NCT05607680
- Nov 17, 2022Phase 3 study in Diabetes Mellitus, Type 2NCT05628311 · 319 enrolled · China
- Mar 20, 20232 phase 1 studiesNCT05815680, NCT05793450
- Dec 1, 20232 phase 3 studiesNCT06164873, NCT06184568
- Jul 25, 2024Phase 1 study in Adolescents With ObesityNCT06536023 · 36 enrolled · China
- Feb 19, 2025Phase 2 study in ObesityNCT06862908 · 141 enrolled · China
- Mar 11, 2025Phase 3 study in OverweightNCT06884293 · 479 enrolled · China
- Apr 7, 2025Phase 2 study in Metabolic Dysfunction-associated Steatohepatitis (MASH)NCT06937749 · 181 enrolled · China
- Apr 9, 2025Phase 3 study in Sleep Apnea SyndromesNCT06931028 · 260 planned · China
- May 8, 2025Phase 2 study in ObesityNCT07000955 · 98 enrolled · China
- Nov 19, 2025Phase 3 study in Adolescents With Obesity or Overweight With Weight-Related ComorbiditiesNCT07255209 · 180 planned · China
- Feb 27, 2026Phase 3 study in OverweightNCT07469800 · 336 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 3 study in OverweightNCT06884293
- May 7, 2027Primary completion: phase 3 study in Sleep Apnea SyndromesNCT06931028
- Oct 31, 2027Primary completion: phase 3 study in Adolescents With Obesity or Overweight With Weight-Related ComorbiditiesNCT07255209
TargetBeta
“Mazdutide is a synthetic peptide analog of mammalian oxyntomodulin and a once-weekly dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), under development for the treatment of obesity and type 2 diabetes (T2D).”study text, by rule · the study
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
All 20 Innovent Biologics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07469800Overweight · China | 3 | Recruiting | Aug 1, 2026 | 336 |
| NCT07255209Adolescents With Obesity or Overweight With Weight-Related Comorbidities · China | 3 | Recruiting | Oct 31, 2027 | 180 |
| NCT07000955Obesity · China | 2 | Active, not recruiting | Sep 30, 2026 | 98 |
| NCT06931028Sleep Apnea Syndromes · China | 3 | Recruiting | May 7, 2027 | 260 |
| NCT06937749Metabolic Dysfunction-associated Steatohepatitis (MASH) · China | 2 | Active, not recruiting | Sep 23, 2026 | 181 |
| NCT06884293Overweight · China | 3 | Active, not recruiting | Dec 31, 2026 | 479 |
| NCT06862908Obesity · China | 2 | Active, not recruiting | Sep 24, 2026 | 141 |
| NCT06536023Adolescents With Obesity · China | 1 | Completed | Jul 22, 2025 | 36 |
| NCT06184568Diabetes Mellitus, Type 2 · China | 3 | Completed | Sep 17, 2025 | 349 |
| NCT06164873Obesity · China | 3 | Active, not recruiting | Jun 27, 2025 | 462 |
| NCT05815680Overweight Subjects · China | 1 | Completed | Aug 18, 2023 | 48 |
| NCT05793450Renal Insufficiency · China | 1 | Completed | Sep 18, 2023 | 20 |
| NCT05628311Diabetes Mellitus, Type 2 · China | 3 | Completed | Oct 25, 2023 | 319 |
| NCT05607680Obesity Or Overweight · China | 3 | Completed | Aug 21, 2023 | 610 |
| NCT05606913Diabetes Mellitus, Type 2 · China | 3 | Completed | Jan 26, 2024 | 731 |
| NCT04965506Diabetes Mellitus, Type 2 · China | 2 | Completed | Apr 28, 2022 | 252 |
| NCT04904913Overweight/ Obesity · China | 2 | Completed | Mar 29, 2023 | 328 |
| NCT04773977Overweight · China | 1 | Completed | Mar 9, 2021 | 24 |
| NCT04466904Diabetes Mellitus, Type 2 · China | 2 | Completed | May 28, 2021 | 42 |
| NCT04440345Overweight · China | 2 | Completed | Jun 16, 2021 | 60 |
How it is read
Names in the registry
- “IBI362”, 19 entries
- “LY3305677”, 5 entries
- “Mazdutide”, 2 entries
- “IBI362 liquid formulation”, 1 entry
- “IBI362 lyophilized powder”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 13 studies
- Diabetes Mellitus, Type 2, 6 studies
- Overweight, 2 studies
- Fatty Liver, 1 study
- Alcoholism, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.